ライフサイエンスコーパス: rotavirus vaccine

1 4.4%) and 64 099 (25.6%) not vaccinated with rotavirus vaccine.

2 hort of infants who received the pentavalent rotavirus vaccine.

3 within 7 days of getting their first dose of rotavirus vaccine.

4 ompared with infants who did not receive the rotavirus vaccine.

5 ccine, whereas one was related to monovalent rotavirus vaccine.

6 ntries that were among the early adopters of rotavirus vaccine.

7 0-March 31, 2001), only 2 stories focused on rotavirus vaccine.

8 ation-sudden condemnation" pattern seen with rotavirus vaccine.

9 evolution may undermine the effectiveness of rotavirus vaccines.

10 strain-specific effectiveness of RV1 and RV5 rotavirus vaccines.

11 ountries and evaluating additional candidate rotavirus vaccines.

12 widely marketed, licensed, live virus, oral rotavirus vaccines.

13 e for monitoring the postlicensure safety of rotavirus vaccines.

14 can infants prior to the introduction of new rotavirus vaccines.

15 cape mutants noted since the introduction of rotavirus vaccines.

16 llance is essential to assess the success of rotavirus vaccines.

17 protection provided by live attenuated oral rotavirus vaccines.

18 use model for active protection studies with rotavirus vaccines.

19 nt and the variety of approaches to creating rotavirus vaccines.

20 or the development of the next generation of rotavirus vaccines.

21 potentially could be prevented by the use of rotavirus vaccines.

22 e design and testing of parenteral candidate rotavirus vaccines.

23 infants who received 1 of several live oral rotavirus vaccines.

24 For the pentavalent rotavirus vaccine, 1,301,810 doses were administered dur

25 We are evaluating subunit rotavirus vaccines, 2/6/7-VLPs and 2/4/6/7-VLPs, that co

26 e significantly less likely to have received rotavirus vaccine (33/44 [73%] unvaccinated) compared wi

27 In a small efficacy trial, the human rotavirus vaccine 89-12 recently has been shown to be sa

28 ssociation between IS and the first licensed rotavirus vaccine, a reassortant-tetravalent, rhesus-bas

29 To facilitate decision making on rotavirus vaccine adoption by countries, help donors pri

30 Effectiveness of 2-3 doses of a rotavirus vaccine against rotavirus requiring emergency

31 declined from 54.8% (95% CI, 48.3%-61.5%) in rotavirus vaccine age-ineligible children to 20.0% (95%

32 ective association exists between receipt of rotavirus vaccine and being hospitalized or visiting the

33 een the tetravalent rhesus-human reassortant rotavirus vaccine and intussusception has increased the

34 Plasma IgA levels specific for antigens in rotavirus vaccine and oral polio vaccine containing poli

35 an association between vaccination with the rotavirus vaccine and the development of intussusception

36 ed implementation of existing interventions (rotavirus vaccine and zinc) are needed to prevent diseas

37 re data has identified a causal link between rotavirus vaccines and intussusception in some settings.

38 We review clinical trial data for available rotavirus vaccines and summarize postlicensure data on e

39 ese processes may aid our ability to develop rotavirus vaccines and therapeutics.

40 was present, after accounting for genogroup, rotavirus vaccine, and age.

41 versity in Europe before the introduction of rotavirus vaccines, and the network will provide a robus

42 The issue was important because rotavirus vaccine, another live oral virus vaccine, was

43 Rotavirus vaccines are a cost-effective intervention and

44 ory and clinical studies, safe and effective rotavirus vaccines are approaching regulatory approval.

45 Two effective rotavirus vaccines are available and recommended for rou

46 As new rotavirus vaccines are being introduced in immunization

47 Second-generation rotavirus vaccines are both highly effective against rot

48 Rotavirus vaccines are delivered early in life, when the

49 As rotavirus vaccines are implemented, studies have been un

50 Several new rotavirus vaccines are in late stages of development.

51 As rotavirus vaccines are introduced globally, monitoring i

52 vaccine in an African setting, especially as rotavirus vaccines are introduced into an increasing num

53 Despite successes, oral rotavirus vaccines are less effective in developing coun

54 ine was associated with intussusception, new rotavirus vaccines are monitored postlicensure for any s

55 Safe, effective, and affordable rotavirus vaccines are needed in these countries.

56 Rotavirus vaccines are now globally recommended by the W

57 Live attenuated rotavirus vaccines are used to protect infants against s

58 nd immunogenicity of the P2-VP8-P[8] subunit rotavirus vaccine at different doses in South African to

59 RotaTeqTM is a pentavalent rotavirus vaccine based on a bovine rotavirus genetic ba

60 ues to recommend that all US infants receive rotavirus vaccine based on the age and precaution/contra

61 There is an urgent need for a rotavirus vaccine, because up to 592,000 infants and you

62 lable on the safety of the second-generation rotavirus vaccines both in the United States and interna

63 itis have declined since the introduction of rotavirus vaccines, but the burden of norovirus-associat

64 The G1P1A[8] rotavirus vaccine candidate 89-12, the precursor to Rota

65 A quadrivalent precursor to the pentavalent rotavirus vaccine candidate RotaTeq was evaluated in a 3

66 otaviruses should be considered as potential rotavirus vaccine candidates for use in Malawi.

67 Several nonliving rotavirus vaccine candidates have been evaluated in anim

68 Several new rotavirus vaccine candidates have now been developed and

69 rhesus macaques in vaccine trials with human rotavirus vaccine candidates is the major objective of f

70 rtant implications for the development of G9 rotavirus vaccine candidates, as the strain with the bro

71 In contrast to live rotavirus vaccines, CD4(+) T cells were found to be the

72 %) one dose, and 136 (25%) no doses of human rotavirus vaccine, compared with 1434 rotavirus-negative

73 Rotarix, an orally administered rotavirus vaccine, contained porcine circovirus-1 (PCV1)

74 As rotavirus vaccines continue to be introduced in Latin Am

75 We sought to determine monovalent rotavirus vaccine cost-effectiveness in Malawi, one of A

76 A rotavirus vaccine could be cost-effective, depending on

77 Introduction of effective and available rotavirus vaccines could substantially affect worldwide

78 Effective rotavirus vaccines could substantially reduce the approx

79 ussus vaccination coverage rates to estimate rotavirus vaccine coverage rates.

80 uncan Steele discuss the evidence supporting rotavirus vaccine deployment in Asian countries.

81 Rotavirus vaccine development began in the early 1980s u

82 Rotavirus vaccine development is a high priority.

83 Since the introduction of rotavirus vaccine, diarrhea-associated health care utili

84 end of 2013, the majority of countries using rotavirus vaccine during the review period were low-mort

85 of US children, we observed that RV5 and RV1 rotavirus vaccines each provided a lasting and broadly h

86 l study at 6 public sector sites to estimate rotavirus vaccine effectiveness (VE) in age-eligible chi

87 We sought to evaluate rotavirus vaccine effectiveness (VE) in this setting.

88 Using data from rotavirus vaccine effectiveness (VE) studies, we assesse

89 ion of rotavirus strains and strain-specific rotavirus vaccine effectiveness after vaccine introducti

90 inform the evaluation of direct and indirect rotavirus vaccine effects in Africa.

91 gnificant correlation between IgA titers and rotavirus vaccine efficacy and hypothesize that a critic

92 e used regional rotavirus disease burden and rotavirus vaccine efficacy data, global natural intussus

93 Rotavirus vaccine efficacy is lower in low-income countr

94 on cases and mortality potentially caused by rotavirus vaccine for each of the 14 countries and compa

95 nd tolerability of a monovalent human-bovine rotavirus vaccine for severe rotavirus gastroenteritis i

96 develop and introduce the next generation of rotavirus vaccines for widespread use.

97 While rotavirus vaccine had been introduced in >60 countries w

98 Three doses of BRV-PV, an oral rotavirus vaccine, had an efficacy of 66.7% against seve

99 An attenuated human rotavirus vaccine has also been developed.

100 ction of children who are age-ineligible for rotavirus vaccine has also been observed in some high an

101 Implementation of rotavirus vaccine has decreased the burden of this disea

102 Rotavirus vaccine has significant implications for the h

103 Rotavirus vaccine has the potential to substantially red

104 Development of live rotavirus vaccines has been highly influenced by views r

105 Implementation of rotavirus vaccines has substantially decreased hospitali

106 and strain changes after the introduction of rotavirus vaccine have been reported.

107 Two rotavirus vaccines have been licensed in >100 countries

108 Two live oral rotavirus vaccines have been licensed in many countries;

109 New rotavirus vaccines have now been developed and extensive

110 Two rotavirus vaccines have recently been licensed for use i

111 In these countries, rotavirus vaccines have reduced all-cause diarrhea and r

112 Two well tolerated and effective rotavirus vaccines have reduced the health burden of rot

113 Two new rotavirus vaccines have shown efficacy against severe ro

114 Current rotavirus vaccines have the potential to greatly reduce

115 The pentavalent human-bovine reassortant rotavirus vaccine (HBRV) is directed against each of the

116 Rotavirus vaccines hold promise to decrease the burden o

117 mmended schedule for receipt of 2-dose human rotavirus vaccine (HRV) coincides with receipt of the fi

118 bella vaccine (MR) and a third dose of human rotavirus vaccine (HRV; MR + HRV), compared with MR give

119 tiveness of a two-dose schedule of the human rotavirus vaccine (HRV; Rotarix) given early at 6 and 10

120 have received at least one dose of the human rotavirus vaccine (ie, those born after June 14, 2009) a

121 strategies should be evaluated for improving rotavirus vaccine immunogenicity in high burden countrie

122 MA) to identify observational evaluations of rotavirus vaccine impact among children <5 years of age

123 Our findings might implicate challenges for rotavirus vaccine implementation in a European populatio

124 rotavirus in Rwanda fell substantially after rotavirus vaccine implementation, including among older

125 pilot introduction of the Rotarix live, oral rotavirus vaccine in all public health facilities in Lus

126 g and establishes the public health value of rotavirus vaccine in an African setting, especially as r

127 6%, 80%, and 86% received 1 or more doses of rotavirus vaccine in each year from 2007 to 2010.

128 The need for a rotavirus vaccine in India is based on the enormous burd

129 is unique project, which is developing a new rotavirus vaccine in India with the use of Indian strain

130 he vaccine effectiveness of monovalent human rotavirus vaccine in preventing admission to hospital fo

131 vaccine effectiveness of 1 or more doses of rotavirus vaccine in preventing rotavirus gastroenteriti

132 Together with the demonstrated impact of rotavirus vaccine in reducing population hospitalization

133 tions raise concerns regarding the safety of rotavirus vaccine in severely immunocompromised patients

134 Successful implementation of any rotavirus vaccine in the developing world requires addit

135 ffects of pneumococcal conjugate vaccine and rotavirus vaccine in the estimation.

136 recast model was used to predict adoption of rotavirus vaccine in the poorest countries in the world.

137 on issued a global recommendation for use of rotavirus vaccines in 2009.

138 WHO recommends routine use of rotavirus vaccines in all countries, particularly in tho

139 round the performance of orally administered rotavirus vaccines in developing countries, vaccine impl

140 nt program, aims to expedite introduction of rotavirus vaccines in India.

141 roduction Plan to close the gap of access to rotavirus vaccines in industrialized and developing coun

142 level of protection detected for the current rotavirus vaccines in low-income versus high-income sett

143 Experience with routine use of rotavirus vaccines in lower middle income countries has

144 ctiveness of RV5 (RotaTeq) and RV1 (Rotarix) rotavirus vaccines in preventing rotavirus gastroenterit

145 lso allow assessment of the effectiveness of rotavirus vaccines in programmatic use and the need for

146 t lower effectiveness and waning immunity of rotavirus vaccines in resource-poor populations.

147 oncerns remain about the performance of oral rotavirus vaccines in these challenging settings.

148 he study period, 207,955 doses of monovalent rotavirus vaccine (including 115,908 first doses and 92,

149 acy stems from studies of previous candidate rotavirus vaccines, including bovine and rhesus rotaviru

150 clinical trials for the current and previous rotavirus vaccines indicate that, as countries begin to

151 unization Hotline during the period in which rotavirus vaccine information was captured (July 1-Decem

152 umented an intussusception risk with current rotavirus vaccines, international data indicate a possib

153 countries in sub-Saharan Africa to introduce rotavirus vaccine into its national immunization program

154 in the Newly Independent States to introduce rotavirus vaccine into its national immunization program

155 ome African country to introduce pentavalent rotavirus vaccine into its routine national immunisation

156 esburg, before and after the introduction of rotavirus vaccine into South Africa's national immunizat

157 For countries that have introduced a rotavirus vaccine into their national immunisation progr

158 recommendation that all countries introduce rotavirus vaccine into their national immunization progr

159 Accelerated development and introduction of rotavirus vaccines into global immunisation programmes h

160 Introduction of rotavirus vaccines into the world's poorest countries is

161 dren during 2006-2015 as a result of the new rotavirus vaccine introduced in 2006.

162 Pre-rotavirus vaccine introduction (2009-2011) and post-rota

163 us vaccine introduction (2009-2011) and post-rotavirus vaccine introduction (2013-2014) periods were

164 ur new estimates can be used to advocate for rotavirus vaccine introduction and to monitor the effect

165 rus vaccination are important for supporting rotavirus vaccine introduction in Africa, where limited

166 of diarrhea requiring hospitalization after rotavirus vaccine introduction in Africa.

167 In anticipation of rotavirus vaccine introduction in Saudi Arabia, this stu

168 ill allow measurement of the rapid impact of rotavirus vaccine introduction on the heavy burden of ro

169 e basis of a $9.18 (53 LE) single-dose cost, rotavirus vaccine introduction would cost the Ministry o

170 Following rotavirus vaccine introduction, a small increase in intu

171 Following rotavirus vaccine introduction, seasonal peaks of rotavi

172 hospitalizations, temporally associated with rotavirus vaccine introduction, was observed in children

173 te watery diarrhea despite a clear impact of rotavirus vaccine introduction.

174 tes before (2000-2005) and after (2007-2009) rotavirus vaccine introduction.

175 ins poorly characterized, particularly after rotavirus vaccine introduction.

176 ted to children 7-18 weeks of age at time of rotavirus vaccine introduction.

177 n-hospital morbidity and mortality following rotavirus vaccine introduction.

178 arrhea deaths captured by HIMS pre- and post-rotavirus vaccine introduction.

179 lacement is a major concern after nationwide rotavirus vaccine introductions.

180 The recently approved rotavirus vaccine is being withheld because of multiple

181 Monovalent human-bovine (116E) rotavirus vaccine is effective and well tolerated in Ind

182 Rotavirus vaccine is effective in preventing rotavirus d

183 Rotavirus vaccine is recommended for routine use in all

184 Live pentavalent human-bovine reassortant rotavirus vaccine is recommended in the United States fo

185 The risk-benefit analysis of rotavirus vaccines is extremely favorable but other stra

186 This decision to develop rotavirus vaccines is predicated on the great burden ass

187 Efficacy of live oral rotavirus vaccines is reduced in low-income compared wit

188 involved in the development of a multivalent rotavirus vaccine, it is important to identify the serot

189 th Organization European Region to introduce rotavirus vaccine (July 2012).

190 RotaShield (Wyeth-Ayerst), the first rotavirus vaccine licensed in the United States, was wit

191 ation formulation, zinc supplementation, and rotavirus vaccines-make now the time to revitalise effor

192 The availability of rotavirus vaccines makes the implementation of a nationa

193 An additional dose of rotavirus vaccine may enhance the immune response and le

194 Several rotavirus vaccines may soon be available for use.

195 New rotavirus vaccines may soon be licensed, and decisions r

196 Parenteral non-replicating rotavirus vaccines might offer benefits over oral vaccin

197 14 Latin American countries currently using rotavirus vaccine must now weigh the health benefits ver

198 of human rotaviruses for change suggest that rotavirus vaccines must provide good heterotypic protect

199 Since the introduction of rotavirus vaccines, norovirus has become the leading cau

200 New safe and effective rotavirus vaccines offer the best hope of reducing the t

201 re low-mortality countries and the impact of rotavirus vaccine on global estimates of rotavirus morta

202 strain replacement after the introduction of rotavirus vaccines, particularly in developing countries

203 Current oral rotavirus vaccines perform suboptimally in resource-poor

204 We aimed to assess the impact of the rotavirus vaccine program and estimate vaccine effective

205 In 2003, the GAVI Alliance launched the Rotavirus Vaccine Program and the Accelerated Developmen

206 coinciding with the introduction of the new rotavirus vaccine program in England.

207 The recent introduction of a rotavirus vaccine program in Mexico to control rotavirus

208 ound direct and herd immunity impacts of the rotavirus vaccine program in young children in the Repub

209 The rotavirus vaccine program is highly cost-effective.

210 The successful introduction of a rotavirus vaccine program was preceded by several decade

211 ether monovalent (RV1) and pentavalent (RV5) rotavirus vaccines provide adequate protection against d

212 This evaluation sought to determine if rotavirus vaccine provided protection through the second

213 Human rotavirus vaccine provided sustained protection against

214 he combined vaccine regimens with individual rotavirus vaccine regimens, we included in the experimen

215 global natural intussusception and regional rotavirus vaccine-related risk estimates, and country-sp

216 A monovalent rotavirus vaccine remains effective against a broad rang

217 Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potent

218 n and immune activation were correlated with rotavirus vaccine responses in 68 human immunodeficiency

219 ors aimed to estimate the effectiveness of a rotavirus vaccine (rhesus rotavirus vaccine-tetravalent

220 There are plans to introduce the oral rotavirus vaccine Rotarix (GlaxoSmithKline), 1 of 2 rece

221 an immunological correlate of protection for rotavirus vaccines (Rotarix [RV1] and RotaTeq [RV5]) wou

222 The oral infant rotavirus vaccine, Rotarix, was introduced in England an

223 Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), wer

224 after vaccination with the live tetravalent rotavirus vaccine RotaShield resulted in voluntary withd

225 temporal association between a first dose of rotavirus vaccine (Rotashield) and infant intussusceptio

226 sure surveillance determined that a previous rotavirus vaccine, RotaShield, caused intussusception in

227 to intussusception events noted with a prior rotavirus vaccine, RotaShield.

228 after vaccination with the second-generation rotavirus vaccines RotaTeq (RV5, a pentavalent vaccine)

229 vaccine effectiveness (VE) of a pentavalent rotavirus vaccine (RotaTeq) against rotavirus diarrhea.

230 amples collected during clinical trials of a rotavirus vaccine (RotaTeq) and identified a serotype in

231 live, pentavalent, human-bovine reassortant rotavirus vaccine (RotaTeq; Merck) in developed countrie

232 ing the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) were reported to the Vaccine

233 ine, a reassortant-tetravalent, rhesus-based rotavirus vaccine (RRV-TV), led to the withdrawal of the

234 live oral vaccine, tetravalent, rhesus-based rotavirus vaccine (RRV-TV), which was incorporated into

235 a surveillance to evaluate monovalent G1P[8] rotavirus vaccine (RV1) efficacy and understand variable

236 (OPV) is known to interfere with monovalent rotavirus vaccine (RV1) immunogenicity.

237 schedule on the immunogenicity of monovalent rotavirus vaccine (RV1) in a developing country.

238 Botswana introduced monovalent G1P rotavirus vaccine (RV1) in July 2012, providing one of t

239 After the introduction of monovalent rotavirus vaccine (RV1) in Mexico in 2006-2007, diarrhea

240 irst African nations to introduce monovalent rotavirus vaccine (RV1) into its childhood immunization

241 Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant i

242 A monovalent human rotavirus vaccine (RV1) was introduced in Botswana in Ju

243 sessed the association of the new monovalent rotavirus vaccine (RV1) with intussusception after routi

244 ndomized controlled trial of monovalent oral rotavirus vaccine (RV1).

245 tion (IS) associated with currently licensed rotavirus vaccines (RV1 [Rotarix; GSK] and RV5 [RotaTeq;

246 vaccination of U.S. infants with pentavalent rotavirus vaccine (RV5) began in 2006.

247 (HEU) African infants receiving pentavalent rotavirus vaccine (RV5) in a clinical trial.

248 Pentavalent rotavirus vaccine (RV5) was introduced into the Israeli

249 Pentavalent rotavirus vaccine (RV5), a live, oral attenuated vaccine

250 Rotavirus vaccine safety and immunogenicity in HIV-infec

251 disease in Rwandan children who began their rotavirus vaccine series from 7 to 18 weeks of age.

252 (WHO) recommended that the efficacy of "new" rotavirus vaccines should be demonstrated in diverse geo

253 Both new rotavirus vaccines showed almost identical rates of intu

254 es in Asia and Africa have demonstrated that rotavirus vaccines significantly reduce severe diarrhea

255 Togo introduced monovalent rotavirus vaccine starting 19 June 2014.

256 Monitoring Services of America databases for rotavirus vaccine stories from the first US clinical tri

257 stlicensure surveillance of a newly licensed rotavirus vaccine suggested an increased risk of intussu

258 effectiveness of a rotavirus vaccine (rhesus rotavirus vaccine-tetravalent (RRV-TV)) to prevent rotav

259 A safe and effective group A rotavirus vaccine that could prevent severe diarrhea or

260 The development of rotavirus vaccines that are based on heterotypic or sero

261 of an increased risk of intussusception with rotavirus vaccine, the 14 Latin American countries curre

262 financial challenges face the global use of rotavirus vaccines, these vaccines-and new candidates in

263 The introduction of rotavirus vaccine to the national immunization program w

264 Adding rotavirus vaccine to the national schedule costs Malawi

265 e modeled the cost-effectiveness of adding a rotavirus vaccine to the Peruvian immunization program u

266 Among 181 Pakistani infants in a G1P[8] rotavirus vaccine trial who were seronegative at baselin

267 The effectiveness of the rotavirus vaccine under conditions of routine use in an

268 For the rotavirus vaccines under development, special attention

269 terminants including age, geography, season, rotavirus vaccine usage, and symptoms.

270 ry 2001 through March 2006, a period without rotavirus vaccine use, by a search of discharge, billing

271 ctiveness estimates and absolute benefits of rotavirus vaccines vary through the years following vacc

272 Because a previous rotavirus vaccine was associated with intussusception, n

273 he administration of two doses of monovalent rotavirus vaccine was estimated to be 5.3 per 100,000 in

274 In Bolivia, monovalent rotavirus vaccine was introduced in 2008 and a previous

275 The monovalent rotavirus vaccine was introduced in Tanzania on 1 Januar

276 Monovalent rotavirus vaccine was introduced in the routine public h

277 Recently a new rotavirus vaccine was licensed in the United States and

278 f children born after 28 February 2006 (when rotavirus vaccine was licensed in the United States) and

279 Rotavirus vaccine was recommended for US infants in 2006

280 Oral rotavirus vaccine was voluntarily withdrawn from the mar

281 tavirus disease before the introduction of a rotavirus vaccine, we aimed to update the estimated numb

282 udy of more than 200,000 doses of monovalent rotavirus vaccine, we observed a significant increase in

283 Two live oral rotavirus vaccines were approved by the US Food and Drug

284 Rotavirus vaccines were initially introduced in Australi

285 By the end of 2008, rotavirus vaccines were licensed in >100 countries, alth

286 In 2006, 2 rotavirus vaccines were licensed.

287 Although current rotavirus vaccines were not associated with an increased

288 Current rotavirus vaccines were not associated with intussuscept

289 Four strains were related to pentavalent rotavirus vaccine, whereas one was related to monovalent

290 Safe, effective rotavirus vaccines will be available soon, and accurate

291 However, it cannot be assumed that rotavirus vaccines will be equally efficacious in infant

292 sception among children receiving monovalent rotavirus vaccine with historical background rates.

293 ne among households whose child had received rotavirus vaccine with those whose child did not receive

294 population for scenarios with and without a rotavirus vaccine with use of data on health outcomes of

295 Rotavirus vaccines with an improved safety profile are u

296 ata for the protective efficacy of the 2 new rotavirus vaccines, with emphasis on issues particularly

297 f 9.5 million infants in these 14 countries, rotavirus vaccine would annually prevent 144 746 (90% co

298 dule versus an unrestricted schedule whereby rotavirus vaccine would be administered with DTP vaccine

299 Assuming rotavirus vaccine would be included in the current Expan

300 overage and timing, a 90% efficacious 3-dose rotavirus vaccine would prevent 70% of deaths due to rot